Boston Scientific (BSX) Stock Forecast & Price Target

$88.07

+1.65 (+1.91%)

(As of 10/18/2024 ET)

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
3

Buy
18

Based on 21 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 3 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$89.10
1.16% Upside

According to the 21 analysts' twelve-month price targets for Boston Scientific, the average price target is $89.10. The highest price target for BSX is $100.00, while the lowest price target for BSX is $68.00. The average price target represents a forecasted upside of 1.16% from the current price of $88.07.

BSX Analyst Ratings Over Time

Type	Current Forecast 10/21/23 to 10/20/24	1 Month Ago 9/21/23 to 9/20/24	3 Months Ago 7/23/23 to 7/22/24	1 Year Ago 10/21/22 to 10/21/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	17 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$89.10	$85.38	$82.29	$60.60
Forecasted Upside	1.16% Upside	1.74% Upside	5.14% Upside	21.08% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Have you heard of Donald Trump’s Project Crypto? (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Learn More Here

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	1.16% Upside	13,587.63% Upside	6.20% Upside
News Sentiment Rating	Positive News See Recent BSX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/18/2024	Stifel Nicolaus 4 of 5 stars	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$85.00 ➝ $100.00	+14.17%
10/18/2024	Needham & Company LLC 2 of 5 stars	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$86.00 ➝ $86.00	-0.50%
10/14/2024	BTIG Research 2 of 5 stars		Boost Target	Buy ➝ Buy	$84.00 ➝ $93.00	+6.72%
10/14/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+14.68%
10/8/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$85.00 ➝ $95.00	+10.65%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$82.00 ➝ $90.00	+7.80%
Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately.
9/4/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$91.00 ➝ $94.00	+15.85%
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $92.00	+15.77%
8/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$78.00 ➝ $86.00	+8.08%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$73.00 ➝ $78.00	+2.63%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$82.00 ➝ $85.00	+8.83%
7/25/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$83.00 ➝ $88.00	+13.17%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$90.00 ➝ $91.00	+17.03%
7/16/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$77.00 ➝ $86.00	+10.16%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$79.00 ➝ $92.00	+17.86%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+20.05%
5/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $95.00	+26.51%
5/15/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$85.00 ➝ $90.00	+22.50%
4/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$74.00 ➝ $90.00	+22.97%
4/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$72.00 ➝ $82.00	+11.58%
2/1/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$58.00 ➝ $68.00	+5.44%
7/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$58.00 ➝ $62.00	+16.43%
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Initiates
6/30/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$64.00	+20.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:43 AM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 10, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

Boston Scientific Co. has shown consistent revenue growth, with a 14.5% increase in revenue year-over-year.
Analysts forecast a positive earnings per share of 2.4 for the current fiscal year, indicating profitability.
Recent institutional trading activity has seen large investors increasing their stakes in the company, signaling confidence in its future performance.
Multiple Wall Street analysts have given Boston Scientific Co. a "buy" or "strong-buy" rating, with price targets well above the current stock price.
The stock price of Boston Scientific Co. has been trading up, reaching $83.24, showing positive momentum in the market.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

Despite positive analyst ratings, there is always a level of risk associated with investing in the stock market, including potential market volatility.
The company operates in the healthcare sector, which can be subject to regulatory changes and unpredictable market conditions.
Insider selling activity has been observed, with company executives selling shares, which could be perceived as a lack of confidence in the company's future prospects.
The stock has a relatively high P/E ratio of 69.88, which may indicate that the stock is currently overvalued compared to its earnings.
While the stock has shown positive growth, past performance is not indicative of future results, and there are no guarantees of continued success.

BSX Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $89.10, with a high forecast of $100.00 and a low forecast of $68.00.
: 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BSX shares.
: According to analysts, Boston Scientific's stock has a predicted upside of 1.16% based on their 12-month stock forecasts.
: Over the previous 90 days, Boston Scientific's stock had 1 downgrade by analysts.
: Boston Scientific has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, and Truist Financial in the past 90 days.
: Analysts like Boston Scientific more than other "medical" companies. The consensus rating score for Boston Scientific is 2.90 while the average consensus rating score for "medical" companies is 2.79. Learn more on how BSX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Man behind OpenAI makes shocking new bet (Ad)

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

Check out our report right here.

This page (NYSE:BSX) was last updated on 10/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Boston Scientific (BSX) Stock Forecast & Price Target